<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Guide to CGRP medications for migraines - new class of preventive and acute migraine treatments including gepants and monoclonal antibodies.">
    <meta name="keywords" content="CGRP, calcitonin gene-related peptide, migraine prevention, Aimovig, Ajovy, gepants">
    <title>CGRP Medications | ChronicSoreness</title>
    <link rel="stylesheet" href="../css/styles.css">
</head>
<body>
    <header class="header"><nav class="nav-container"><div class="logo"><a href="../index.html"><span class="logo-icon">ðŸ’œ</span><span class="logo-text"><strong>Chronic</strong>Soreness</span></a></div><button class="mobile-menu-toggle" aria-label="Toggle menu"><span class="hamburger"></span></button><ul class="nav-menu"><li><a href="../conditions.html">Conditions</a></li><li><a href="../treatments.html">Treatments</a></li><li><a href="../medications.html">Medications</a></li><li><a href="../exercise.html">Exercise</a></li><li><a href="../nutrition.html">Nutrition</a></li><li><a href="../mental-health.html">Mental Health</a></li></ul></nav></header>
    <main id="main-content">
        <article class="page-header"><h1>CGRP Medications</h1><p>New targeted treatments for migraines</p></article>
        <section class="content-section">
            <div class="container">
                <h2>What Is CGRP?</h2>
                <p>Calcitonin gene-related peptide (CGRP) is a protein that plays a key role in migraine. During migraine attacks, CGRP is released and causes blood vessel dilation and inflammation. Blocking CGRP can prevent and treat migraines.<sup>1</sup></p>

                <h2>Types of CGRP Medications</h2>
                <h3>Monoclonal Antibodies (Prevention)<sup>2</sup></h3>
                <ul>
                    <li><strong>Erenumab (Aimovig)</strong> - Monthly injection</li>
                    <li><strong>Fremanezumab (Ajovy)</strong> - Monthly or quarterly</li>
                    <li><strong>Galcanezumab (Emgality)</strong> - Monthly injection</li>
                    <li><strong>Eptinezumab (Vyepti)</strong> - IV infusion quarterly</li>
                </ul>

                <h3>Gepants (Acute and Prevention)</h3>
                <ul>
                    <li><strong>Ubrogepant (Ubrelvy)</strong> - Acute treatment</li>
                    <li><strong>Rimegepant (Nurtec)</strong> - Acute and prevention</li>
                    <li><strong>Atogepant (Qulipta)</strong> - Prevention</li>
                </ul>

                <h2>Benefits<sup>3</sup></h2>
                <ul>
                    <li>Designed specifically for migraine</li>
                    <li>Good efficacy in clinical trials</li>
                    <li>Fewer side effects than many older preventives</li>
                    <li>No cardiovascular contraindications</li>
                    <li>Option for patients who failed other treatments</li>
                </ul>

                <h2>Side Effects</h2>
                <h3>Monoclonal Antibodies</h3>
                <ul>
                    <li>Injection site reactions</li>
                    <li>Constipation (most common)</li>
                    <li>Generally well tolerated</li>
                </ul>

                <h3>Gepants</h3>
                <ul>
                    <li>Nausea</li>
                    <li>Drowsiness</li>
                    <li>Generally mild</li>
                </ul>

                <h2>Who May Benefit</h2>
                <ul>
                    <li>4+ migraine days per month</li>
                    <li>Failed or can't tolerate other preventives</li>
                    <li>Contraindications to other options</li>
                    <li>Chronic migraine</li>
                </ul>

                <h2>References</h2>
                <ol>
                    <li>Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies. <em>Nat Rev Neurol</em>. 2018;14(6):338-350.</li>
                    <li>Silberstein SD, Holland S. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention. <em>Neurology</em>. 2012;78(17):1337-1345.</li>
                    <li>Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine. <em>JAMA</em>. 2018;319(19):1999-2008.</li>
                </ol>
            </div>
        </section>
    </main>
    <footer class="footer"><div class="container"><p class="disclaimer">The information provided is for educational purposes only and is not medical advice.</p><p class="copyright">Â© 2024 ChronicSoreness. All rights reserved.</p></div></footer>
    <script src="../js/main.js"></script>
</body>
</html>
